EQUILLIUM, INC. Payments to Acquire Short-term Investments
EQUILLIUM, INC. (EQ) reported Payments to Acquire Short-term Investments of $17.60 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-03-25
- EQUILLIUM, INC. payments to acquire short-term investments for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- EQUILLIUM, INC. payments to acquire short-term investments for the quarter ending 2024-09-30 was $0.00.
- EQUILLIUM, INC. payments to acquire short-term investments for the quarter ending 2024-06-30 was $10.29M.
- EQUILLIUM, INC. payments to acquire short-term investments for the quarter ending 2024-03-31 was $7.31M, a 80.33% decline year-over-year.
- EQUILLIUM, INC. payments to acquire short-term investments for fiscal 2024 was $17.60M, a 67.83% decline from fiscal 2023.
- EQUILLIUM, INC. payments to acquire short-term investments for fiscal 2023 was $54.71M, a 265.67% increase from fiscal 2022.
- EQUILLIUM, INC. payments to acquire short-term investments for fiscal 2022 was $14.96M, a 54.65% decline from fiscal 2021.
- EQUILLIUM, INC. payments to acquire short-term investments for fiscal 2021 was $32.99M, a 40.57% decline from fiscal 2020.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month | Payments to Acquire Short-term Investments 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | $10.29M derived: sum of 3 quarters · filed 2026-03-25 | $17.60M 10-K · filed 2026-03-25 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $10.29M derived: sum of 2 quarters · filed 2025-11-13 | $17.60M 10-Q · filed 2025-11-13 | $35.13M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $10.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $17.60M 10-Q · filed 2025-08-14 | $35.13M derived: sum of 3 quarters · filed 2025-08-14 | $35.13M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $7.31M 10-Q · filed 2025-05-14 | $24.84M derived: sum of 2 quarters · filed 2025-05-14 | $24.84M derived: sum of 3 quarters · filed 2025-05-14 | $24.84M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $17.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $17.53M derived: sum of 2 quarters · filed 2025-03-27 | $17.53M derived: sum of 3 quarters · filed 2025-03-27 | $54.71M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $37.18M 10-Q · filed 2024-11-13 | $37.18M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $37.18M 10-Q · filed 2024-08-08 | $37.18M derived: sum of 3 quarters · filed 2024-08-08 | $37.18M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $37.18M 10-Q · filed 2024-05-09 | $37.18M derived: sum of 2 quarters · filed 2024-05-09 | $37.18M derived: sum of 3 quarters · filed 2024-05-09 | $37.18M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $0.00 derived: sum of 2 quarters · filed 2024-03-25 | $0.00 derived: sum of 3 quarters · filed 2024-03-25 | $14.96M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $14.96M 10-Q · filed 2023-11-08 | $34.35M derived: sum of 4 quarters · filed 2023-11-08 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $14.96M 10-Q · filed 2023-08-09 | $34.35M derived: sum of 3 quarters · filed 2023-08-09 | $40.35M derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | $14.96M 10-Q · filed 2023-05-11 | $34.35M derived: sum of 2 quarters · filed 2023-05-11 | $40.35M derived: sum of 3 quarters · filed 2023-05-11 | $40.35M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $19.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $25.39M derived: sum of 2 quarters · filed 2023-03-23 | $25.39M derived: sum of 3 quarters · filed 2023-03-23 | $32.99M 10-K · filed 2023-03-23 | |
| 2021-09-30 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $6.00M derived: sum of 2 quarters · filed 2022-11-14 | $13.60M 10-Q · filed 2022-11-14 | $38.80M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $7.61M 10-Q · filed 2022-08-15 | $32.80M derived: sum of 3 quarters · filed 2022-08-15 | $60.89M derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | $7.61M 10-Q · filed 2022-05-12 | $32.80M derived: sum of 2 quarters · filed 2022-05-12 | $60.89M derived: sum of 3 quarters · filed 2022-05-12 | $60.89M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $25.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $53.28M derived: sum of 2 quarters · filed 2022-03-23 | $53.28M derived: sum of 3 quarters · filed 2022-03-23 | $55.51M 10-K · filed 2022-03-23 | |
| 2020-09-30 | $28.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $28.09M derived: sum of 2 quarters · filed 2021-11-10 | $30.31M 10-Q · filed 2021-11-10 | $48.84M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $2.23M 10-Q · filed 2021-08-10 | $20.75M derived: sum of 3 quarters · filed 2021-08-10 | $31.21M derived: sum of 4 quarters · filed 2021-08-10 | |
| 2020-03-31 | $2.23M 10-Q · filed 2021-05-13 | $20.75M derived: sum of 2 quarters · filed 2021-05-13 | $31.21M derived: sum of 3 quarters · filed 2021-05-13 | $42.63M derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | $18.52M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $28.99M derived: sum of 2 quarters · filed 2021-03-24 | $40.40M derived: sum of 3 quarters · filed 2021-03-24 | $54.62M 10-K · filed 2021-03-24 | |
| 2019-09-30 | $10.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $21.88M derived: sum of 2 quarters · filed 2020-11-10 | $36.09M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $11.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $25.63M 10-Q · filed 2020-08-12 | |||
| 2019-03-31 | $14.21M 10-Q · filed 2020-05-13 | ||||
| 2018-12-31 | $37.40M 10-K · filed 2020-03-26 | $37.40M 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |